How to appeal a Blue Cross NC growth hormone replacement therapy denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Blue Cross NC-specific note: BCBS licensee for North Carolina (~4.3M members). Prime Therapeutics PBM. NC DOI oversight. Blue Premier is the high-profile value-based care program. Recently divested some Medicaid business; Healthy Blue (joint venture with Elevance) handles NC Medicaid.

What Blue Cross NC's policy requires for growth hormone replacement therapy

Cited policy: BCBS Ngenla (Somatrogon-ghla) Once-Weekly GH PA

Pediatric GHD age >=3 yr per FDA Jun 27 2023 label. Two provocative GH stim tests with peak GH <10 ng/mL (BMI-adjusted). IGF-1 SDS low. Pituitary MRI. Endocrinologist Rx. Step-therapy: prior 6-12 mo daily somatropin trial typically required unless contraindicated or adherence-limited. Reauth at 12 mo with HV + IGF-1 response.

How Blue Cross NC denies growth hormone replacement therapy — and how to counter it

Where Blue Cross NC pushes back: 1) Weekly GH experimental / investigational; 2) Cheaper daily somatropin available — clinically equivalent; 3) Brand-on-formulary forced switch (must use Skytrofa / Sogroya).

Counter-arguments that hold up: Ngenla FDA-approved Jun 27 2023 — Deal JCEM 2022 Phase 3 (n=224 treatment-naive peds GHD) non-inferior AHV vs daily somatropin at 12 mo. PES 2022 statement supports weekly GH options. Adherence with daily injections documented poor — KIGS registry. Document specific daily-GH adherence failure / device intolerance / caregiver burden / school + sports avoidance. Ngenla device platform (single-use prefilled pen, room-temp stable 4 days) differs materially from Skytrofa (TransCon prodrug Auto-Injector) and Sogroya (FlexTouch pen) — patient-fit selection is medically necessary, not interchangeable. Cite Social Security Act 1927(d)(4) brand-medical-necessity.

What Blue Cross NC typically denies for growth hormone replacement therapy

Across Blue Cross NC's commercial and Medicare books, denials cluster around a small number of patterns. For growth hormone replacement therapy, expect:

• Step therapy via Prime Therapeutics
• Blue Premier value-based arrangement disputes
• Out-of-network reductions
• Specialty drug PA

Treatments most often denied in this category

These are the growth hormone replacement therapy treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Norditropin (daily)
• Genotropin (daily)
• Humatrope (daily)
• Saizen (daily)
• Omnitrope (biosimilar daily)
• Nutropin AQ (daily)

How to submit the appeal to Blue Cross NC

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Blue Cross NC cited in the denial.
3. File the appeal through Blue Cross NC's portal (members: https://www.bluecrossnc.com ; providers: https://www.bluecrossnc.com/providers). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In NC, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Blue Cross NC's prior-authorization criteria by drug: Blue Cross NC PA criteria on ApprovalHelp.